Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
This study was a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3"
design to determine maximum tolerated dose/recommended Phase 2 dose.